ASH 2019 | Liso-cel induces rapid uMRD: TRANSCEND CLL 004 update

Tanya Siddiqi, MD, City of Hope, Duarte, CA, presents the latest updates from the TRANSCEND CLL 004 trial (NCT03331198) of lisocabtagene maraleucel in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). She covers the exciting rapid, undetectable MRD responses observed in patients with relapsed/refractory CLL/SLL, and discusses the safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.